Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Saturn Oil & Gas Inc. Announces its First Development of Cardium Wells at Brazeau and Continued Successful Development (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News ESSA Pharma Inc EPIX

Healthcare Biotechnology
ESSA Pharma Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is focused on developing proprietary therapies for the treatment of patients with prostate cancer. Its lead candidate, EPI-7386, is an oral, small molecule that inhibits the N-terminal domain of the androgen receptor (AR). The Company is completing the initial Phase I clinical development of EPI-7386 as a... see more

Recent & Breaking News (NDAQ:EPIX)

ESSA Pharma to Present at the Oppenheimer 33rd Annual Healthcare Conference

PR Newswire March 8, 2023

ESSA Pharma Announces Presentations at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU)

PR Newswire February 13, 2023

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2022

PR Newswire February 7, 2023

ESSA Pharma to Participate in the Guggenheim Healthcare Talks 5th Annual Oncology Conference

PR Newswire February 2, 2023

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2022

PR Newswire December 13, 2022

ESSA Pharma to Participate in Two Upcoming Investor Conferences

PR Newswire November 10, 2022

ESSA Provides an Update on its Clinical Collaboration with Janssen

PR Newswire October 31, 2022

ESSA Pharma Presents Preclinical Data for its First Generation Androgen Receptor N-Terminal Domain Degrader at the 34th EORTC-NCI-AACR Symposium

PR Newswire October 26, 2022

Updated Results from the Phase 1/2 Study of ESSA's Lead Candidate EPI-7386 in Combination with Enzalutamide Highlighted at the 29th Annual Prostate Cancer Foundation Scientific Retreat

PR Newswire October 26, 2022

ESSA Pharma Appoints Philip Kantoff to its Board of Directors

PR Newswire September 13, 2022

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2022

PR Newswire August 4, 2022

ESSA Pharma Insiders Establish Automatic Securities Disposition Plans

Canada NewsWire June 30, 2022

ESSA Pharma Presents Clinical Update on EPI-7386 Monotherapy and Combination Therapy Clinical Development

PR Newswire June 27, 2022

ESSA Pharma to Present at 2022 Jefferies Healthcare Conference

PR Newswire June 2, 2022

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2022

PR Newswire May 10, 2022

ESSA Pharma to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference

PR Newswire April 26, 2022

ESSA Pharma Announces the Presentation of Preclinical Data for its First Generation of Androgen Receptor N-Terminal Domain Degraders

PR Newswire April 8, 2022

ESSA Pharma to Present at Oppenheimer Annual Healthcare Conference

PR Newswire March 10, 2022

ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS

PR Newswire March 9, 2022

ESSA Pharma to Present Preclinical Data for its First Generation of Androgen Receptor N-Terminal Domain Degraders at the 2022 American Association for Cancer Research (AACR) Annual Meeting

PR Newswire March 8, 2022